다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Current molecular pharmacology, v.14, 2021년, pp.179 - 189
He, Xin-Ling (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China) , Xu, Xiao-Huang (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China) , Shi, Jia-Jie (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China) , Huang, Mingqing (College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122,China) , Wang, Yitao (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China) , Chen, Xiuping (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China) , Lu, Jin-Jian (State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao,China)
AI-Helper
Background:As one of the effective pharmacological constituents of Ginseng Radix et Rhizoma, ginsenoside Rh2 (Rh2) exerts a remarkable anticancer effect on various cancer cell lines in vitro and strongly inhibits tumor growth in vivo without severe toxicity.Objective:This article reviewed existing e...
Chin J Integr Med Li X.Y. 25 883 2019 10.1007/s11655-019-3046-2 Li X.Y.; Sun L.W.; Zhao D.Q.; Current Status and Problem-Solving Strategies for Ginseng Industry. Chin J Integr Med 2019,25(12),883-886
Molecules Chen W 24 3491 2019 10.3390/molecules24193491 Chen W; Balan P.; Analysis of Ginsenoside Content (Panax ginseng) from Different Regions. Molecules 2019,24(19),3491
Phytother Res Xiang Y.Z. 22 851 2008 10.1002/ptr.2384 Xiang Y.Z.; Shang H.C.; Gao X.M.; Zhang B.L.; A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological Molecules experiments and clinical trials. Phytother Res 2008,22(7),851-858
J Chromatogr B Analyt Technol Biomed Life Sci Yuan J. 1038 1 2016 10.1016/j.jchromb.2016.10.014 Yuan J.; Chen Y.; Liang J.; Wang C.Z.; Liu X.; Yan Z.; Tang Y.; Li J.; Yuan C.S.; Component analysis and target cell-based neuroactivity screening of Panax ginseng by ultra-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016,1038,1-11
Molecules Cheng Z. 24 1102 2019 10.3390/molecules24061102 Cheng Z.; Zhang M.; Ling C.; Zhu Y.; Ren H.; Hong C.; Qin J.; Liu T.; Wang J.; Neuroprotective Effects of Ginsenosides against Cerebral Ischemia. Molecules 2019,24(6),1102
Food Funct Liu Y. 10 2538 2019 10.1039/C9FO00095J Liu Y.; Deng J.; Fan D.; Ginsenoside Rk3 ameliorates high-fat-diet/streptozocin induced type 2 diabetes mellitus in mice via the AMPK/Akt signaling pathway. Food Funct 2019,10(5),2538-2551
Curr Top Med Chem Guo Y.H. 19 2334 2019 10.2174/1568026619666191018100848 Guo Y.H.; Kuruganti R.; Gao Y.; Recent Advances in Ginsenosides as Potential Therapeutics Against Breast Cancer. Curr Top Med Chem 2019,19(25),2334-2347
World J Tradit Chin Med 5 42 2019 10.4103/wjtcm.wjtcm_3_19 Gao, S.H.; Zhao, D.D.; Bai, Y.; Wu, R.; Mo, F.F.; Liu, C.Y. Effects of ginsenoside Rb1 on skeletal muscle insulin resistance and adenosine monophosphate-activated protein kinase signaling pathway in obese mice. World J Tradit Chin Med 2019,5(1),42
Chin Med Luo H. 14 48 2019 10.1186/s13020-019-0270-9 Luo H.; Vong C.T.; Chen H.; Gao Y.; Lyu P.; Qiu L.; Zhao M.; Liu Q.; Cheng Z.; Zou J.; Yao P.; Gao C.; Wei J.; Ung C.O.L.; Wang S.; Zhong Z.; Wang Y.; Naturally occurring anti- cancer compounds: shining from Chinese herbal medicine. Chin Med 2019,14(1),48
Molecules Xu X.H. 21 1326 2016 10.3390/molecules21101326 Xu X.H.; Li T.; Fong C.M.V.; Chen X.; Chen X.J.; Wang Y.T.; Huang M.Q.; Lu J.J.; Saponins from Chinese Medicines as Anticancer Agents. Molecules 2016,21(10),1326
Biol Pharm Bull Bae E.A. 25 58 2002 10.1248/bpb.25.58 Bae E.A.; Han M.J.; Choo M.K.; Park S.Y.; Kim D.H.; Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull 2002,25(1),58-63
Acta Pharmacol Sin Choi K.T. 29 1109 2008 10.1111/j.1745-7254.2008.00869.x Choi K.T.; Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008,29(9),1109-1118
Xenobiotica Bae S.H. 44 1099 2014 10.3109/00498254.2014.929192 Bae S.H.; Park J.B.; Zheng Y.F.; Jang M.J.; Kim S.O.; Kim J.Y.; Yoo Y.H.; Yoon K.D.; Oh E.; Bae S.K.; Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats. Xenobiotica 2014,44(12),1099-1107
Biol Pharm Bull Cheong J.H. 38 102 2015 10.1248/bpb.b14-00603 Cheong J.H.; Kim H.; Hong M.J.; Yang M.H.; Kim J.W.; Yoo H.; Yang H.; Park J.H.; Sung S.H.; Kim H.P.; Kim J.; Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 in HepG2 cells: disparity in cytotoxicity and autophagy-inducing effects due to 20(S)-epimers. Biol Pharm Bull 2015,38(1),102-108
Acta Biochim Biophys Sin (Shanghai) Huang J. 48 750 2016 10.1093/abbs/gmw049 Huang J.; Peng K.; Wang L.; Wen B.; Zhou L.; Luo T.; Su M.; Li J.; Luo Z.; Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-α signaling pathway. Acta Biochim Biophys Sin (Shanghai) 2016,48(8),750-755
Carcinogenesis Chung K.S. 34 331 2013 10.1093/carcin/bgs341 Chung K.S.; Cho S.H.; Shin J.S.; Kim D.H.; Choi J.H.; Choi S.Y.; Rhee Y.K.; Hong H.D.; Lee K.T.; Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression. Carcinogenesis 2013,34(2),331-340
Chem Biol Interact Liu Z.H. 242 227 2015 10.1016/j.cbi.2015.10.014 Liu Z.H.; Li J.; Xia J.; Jiang R.; Zuo G.W.; Li X.P.; Chen Y.; Xiong W.; Chen D.L.; Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells. Chem Biol Interact 2015,242,227-234
Biol Pharm Bull Ge G. 40 2117 2017 10.1248/bpb.b17-00463 Ge G.; Yan Y.; Cai H.; Ginsenoside Rh2 Inhibited Proliferation by Inducing ROS Mediated ER Stress Dependent Apoptosis in Lung Cancer Cells. Biol Pharm Bull 2017,40(12),2117-2124
Cancer Chemother Pharmacol Cheng C.C. 55 531 2005 10.1007/s00280-004-0919-6 Cheng C.C.; Yang S.M.; Huang C.Y.; Chen J.C.; Chang W.M.; Hsu S.L.; Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol 2005,55(6),531-540
Front Pharmacol Zhang J. 10 1331 2019 10.3389/fphar.2019.01331 Zhang J.; Li W.; Yuan Q.; Zhou J.; Zhang J.; Cao Y.; Fu G.; Hu W.; Transcriptome Analyses of the Anti-Proliferative Effects of 20(S)-Ginsenoside Rh2 on HepG2 Cells. Front Pharmacol 2019,10,1331
Sci Rep Yang Z. 6 19383 2016 10.1038/srep19383 Yang Z.; Zhao T.; Liu H.; Zhang L.; Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep 2016,6,19383
Eur J Pharmacol Li Q. 815 173 2017 10.1016/j.ejphar.2017.09.023 Li Q.; Li B.; Dong C.; Wang Y.; Li Q.; 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription. Eur J Pharmacol 2017,815,173-180
Oncol Rep Shi Q. 36 2059 2016 10.3892/or.2016.5033 Shi Q.; Shi X.; Zuo G.; Xiong W.; Li H.; Guo P.; Wang F.; Chen Y.; Li J.; Chen D.L.; Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin. Oncol Rep 2016,36(4),2059-2070
J Agric Food Chem Chen F. 64 253 2016 10.1021/acs.jafc.5b05450 Chen F.; Deng Z.Y.; Zhang B.; Xiong Z.X.; Zheng S.L.; Tan C.L.; Hu J.N.; Esterification of Ginsenoside Rh2 Enhanced Its Cellular Uptake and Antitumor Activity in Human HepG2 Cells. J Agric Food Chem 2016,64(1),253-261
World J Gastroenterol Tang X.P. 19 1582 2013 10.3748/wjg.v19.i10.1582 Tang X.P.; Tang G.D.; Fang C.Y.; Liang Z.H.; Zhang L.Y.; Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol 2013,19(10),1582-1592
Cancer Lett Li B. 301 185 2011 10.1016/j.canlet.2010.11.015 Li B.; Zhao J.; Wang C.Z.; Searle J.; He T.C.; Yuan C.S.; Du W.; Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011,301(2),185-192
J Ethnopharmacol Han S. 194 83 2016 10.1016/j.jep.2016.08.039 Han S.; Jeong A.J.; Yang H.; Bin Kang K.; Lee H.; Yi E.H.; Kim B.H.; Cho C.H.; Chung J.W.; Sung S.H.; Ye S.K.; Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. J Ethnopharmacol 2016,194,83-90
Hum Cell Liu G.W. 31 189 2018 10.1007/s13577-017-0189-3 Liu G.W.; Liu Y.H.; Jiang G.S.; Ren W.D.; The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell 2018,31(3),189-198
Pharm Res Choi S. 26 2280 2009 10.1007/s11095-009-9944-9 Choi S.; Kim T.W.; Singh S.V.; Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res 2009,26(10),2280-2288
J Cell Biochem Choi S. 112 330 2011 10.1002/jcb.22932 Choi S.; Oh J.Y.; Kim S.J.; Ginsenoside Rh2 induces Bcl-2 family proteins-mediated apoptosis in vitro and in xenografts in vivo models. J Cell Biochem 2011,112(1),330-340
Anticancer Drugs Kikuchi Y. 2 63 1991 10.1097/00001813-199102000-00009 Kikuchi Y.; Sasa H.; Kita T.; Hirata J.; Tode T.; Nagata I.; Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 1991,2(1),63-67
Mol Med Rep Shi X. 17 4811 2018 10.3892/mmr.2018.8454 Shi X.; Yang J.; Wei G.; Ginsenoside 20(S)-Rh2 exerts anti- cancer activity through the Akt/GSK3β signaling pathway in human cervical cancer cells. Mol Med Rep 2018,17(3),4811-4816
Biomed Pharmacother Kim J.H. 96 871 2017 10.1016/j.biopha.2017.09.033 Kim J.H.; Kim M.; Yun S.M.; Lee S.; No J.H.; Suh D.H.; Kim K.; Kim Y.B.; Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells. Biomed Pharmacother 2017,96,871-876
Fitoterapia Liu J. 81 902 2010 10.1016/j.fitote.2010.05.020 Liu J.; Shimizu K.; Yu H.; Zhang C.; Jin F.; Kondo R.; Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia 2010,81(7),902-905
Tumour Biol Zhang Q. 36 2377 2015 10.1007/s13277-014-2845-5 Zhang Q.; Hong B.; Wu S.; Niu T.; Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour Biol 2015,36(4),2377-2381
Int J Oncol Oh M. 14 869 1999 10.3892/ijo.14.5.869 Oh M.; Choi Y.H.; Choi S.; Chung H.; Kim K.; Kim S.I.; Kim D.K.; Kim N.D.; Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999,14(5),869-875
Nat Rev Clin Oncol Carneiro B.A. 17 395 2020 10.1038/s41571-020-0341-y Carneiro B.A.; El-Deiry W.S.; Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 2020,17(7),395-417
Biol Pharm Bull Xia T. 37 248 2014 10.1248/bpb.b13-00667 Xia T.; Wang J.C.; Xu W.; Xu L.H.; Lao C.H.; Ye Q.X.; Fang J.P.; 20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways. Biol Pharm Bull 2014,37(2),248-254
Genet Mol Res Liu X. 15 15039003 2016 10.4238/gmr.15039003 Liu X.; Sun Y.; Yue L.; Li S.; Qi X.; Zhao H.; Yang Y.; Zhang C.; Yu H.; JNK pathway and relative transcriptional factor were involved in ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Genet Mol Res 2016,15(3),15039003
Oncotarget Tong-Lin Wu T. 9 11109 2018 10.18632/oncotarget.24326 Tong-Lin Wu T.; Tong Y.C.; Chen I.H.; Niu H.S.; Li Y.; Cheng J.T.; Induction of apoptosis in prostate cancer by ginsenoside Rh2. Oncotarget 2018,9(13),11109-11118
Br J Pharmacol Park E.K. 160 1212 2010 10.1111/j.1476-5381.2010.00768.x Park E.K.; Lee E.J.; Lee S.H.; Koo K.H.; Sung J.Y.; Hwang E.H.; Park J.H.; Kim C.W.; Jeong K.C.; Park B.K.; Kim Y.N.; Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. Br J Pharmacol 2010,160(5),1212-1223
Int J Mol Sci Guo X.X. 13 15523 2012 10.3390/ijms131215523 Guo X.X.; Guo Q.; Li Y.; Lee S.K.; Wei X.N.; Jin Y.H.; Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase-9/caspase-8 activation. Int J Mol Sci 2012,13(12),15523-15535
Food Chem Toxicol Park H 50 2736 2012 10.1016/j.fct.2012.05.027 Park H; Kim S; Kim J; Kang H.; Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol 2012,50(8),2736-2741
Cell Biochem Biophys Chen W. 72 325 2015 10.1007/s12013-014-0456-9 Chen W.; Qiu Y.; Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma. Cell Biochem Biophys 2015,72(2),325-331
Biochim Biophys Acta Rev Cancer Fontana F. 1873 188338 2020 10.1016/j.bbcan.2020.188338 Fontana F.; Raimondi M.; Marzagalli M.; Di Domizio A.; Limonta P.; The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer 2020,1873(2),188338
Biomed Pharmacother Wang Y 118: 109203 2019 10.1016/j.biopha.2019.109203 Wang Y; Wen X; Zhang N; Wang L; Hao D; Jiang X; Small- molecule compounds target paraptosis to improve cancer therapy. Biomed Pharmacother 2019,118: 109203
Pharmacol Ther Lee D. 162 120 2016 10.1016/j.pharmthera.2016.01.003 Lee D.; Kim I.Y.; Saha S.; Choi K.S.; Paraptosis in the anti- cancer arsenal of natural products. Pharmacol Ther 2016,162,120-133
Cancer Onorati A.V. 124 3307 2018 10.1002/cncr.31335 Onorati A.V.; Dyczynski M.; Ojha R.; Amaravadi R.K.; Targeting autophagy in cancer. Cancer 2018,124(16),3307-3318
Cancer Deng S. 125 1228 2019 10.1002/cncr.31978 Deng S.; Shanmugam M.K.; Kumar A.P.; Yap C.T.; Sethi G.; Bishayee A.; Targeting autophagy using natural compounds for cancer prevention and therapy. Cancer 2019,125(8),1228-1246
Nutrients Zhuang J. 10 328 2018 10.3390/nu10030328 Zhuang J.; Yin J.; Xu C.; Mu Y.; Lv S.; 20(S)-Ginsenoside Rh2 Induce the Apoptosis and Autophagy in U937 and K562 Cells. Nutrients 2018,10(3),328
Exp Mol Pathol Li M. 108 17 2019 10.1016/j.yexmp.2019.03.004 Li M.; Zhang D.; Cheng J.; Liang J.; Yu F.; Ginsenoside Rh2 inhibits proliferation but promotes apoptosis and autophagy by down-regulating microRNA-638 in human retinoblastoma cells. Exp Mol Pathol 2019,108,17-23
Biochem Biophys Res Commun Yang D. 522 300 2020 10.1016/j.bbrc.2019.11.026 Yang D.; Li X.; Zhang X.; Ginsenoside Rh2 induces DNA damage and autophagy in vestibular schwannoma is dependent of LAMP2 transcriptional suppression. Biochem Biophys Res Commun 2020,522(2),300-307
Eur J Cancer Monteiro J. 46 1198 2010 10.1016/j.ejca.2010.02.030 Monteiro J.; Fodde R.; Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 2010,46(7),1198-1203
Nat Rev Cancer Steeg P.S. 16 201 2016 10.1038/nrc.2016.25 Steeg P.S.; Targeting metastasis. Nat Rev Cancer 2016,16(4),201-218
Biomolecules Wang Y.S. 10 528 2020 10.3390/biom10040528 Wang Y.S.; Li H.; Li Y.; Zhang S.; Jin Y.H.; (20S)G-Rh2 Inhibits NF-κB Regulated Epithelial-Mesenchymal Transition by Targeting Annexin A2. Biomolecules 2020,10(4),528
Biochem Pharmacol Kim S.Y. 74 1642 2007 10.1016/j.bcp.2007.08.015 Kim S.Y.; Kim D.H.; Han S.J.; Hyun J.W.; Kim H.S.; Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells. Biochem Pharmacol 2007,74(11),1642-1651
BMC Cancer Li H. 18 579 2018 10.1186/s12885-018-4299-4 Li H.; Huang N.; Zhu W.; Wu J.; Yang X.; Teng W.; Tian J.; Fang Z.; Luo Y.; Chen M.; Li Y.; Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2. BMC Cancer 2018,18(1),579
Adv Drug Deliv Rev Veith A.P. 146 97 2019 10.1016/j.addr.2018.09.010 Veith A.P.; Henderson K.; Spencer A.; Sligar A.D.; Baker A.B.; Therapeutic strategies for enhancing angiogenesis in wound healing. Adv Drug Deliv Rev 2019,146,97-125
Adv Drug Deliv Rev Roudsari L.C. 97 250 2016 10.1016/j.addr.2015.11.004 Roudsari L.C.; West J.L.; Studying the influence of angiogenesis in in vitro cancer model systems. Adv Drug Deliv Rev 2016,97,250-259
J Nanosci Nanotechnol Huang Y. 19 1942 2019 10.1166/jnn.2019.16404 Huang Y.; Huang H.; Han Z.; Li W.; Mai Z.; Yuan R.; Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1. J Nanosci Nanotechnol 2019,19(4),1942-1950
Exp Ther Med Ma J. 18 630 2019 10.3892/etm.2019.7604 Ma J.; Gao G.; Lu H.; Fang D.; Li L.; Wei G.; Chen A.; Yang Y.; Zhang H.; Huo J.; Reversal effect of ginsenoside Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism. Exp Ther Med 2019,18(1),630-636
Inc Taube J.M. 31 214 2018 Taube J.M.; Galon J.; Sholl L.M.; Rodig S.J.; Cottrell T.R.; Giraldo A.G.; Implications of the tumor immune microenvironment for staging and therapeutics. Mod. Pathol Inc 2018,31(2),214-234
Cancer Treat Rev Belli C. 65 22 2018 10.1016/j.ctrv.2018.02.004 Belli C.; Trapani D.; Viale G.; D’Amico P.; Duso B.A.; Della Vigna P.; Orsi F.; Curigliano G.; Targeting the microenvironment in solid tumors. Cancer Treat Rev 2018,65,22-32
Trends Cell Biol Klemm F. 25 198 2015 10.1016/j.tcb.2014.11.006 Klemm F.; Joyce J.A.; Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 2015,25(4),198-213
Oncol Lett Wang M. 13 681 2017 10.3892/ol.2016.5490 Wang M.; Yan S.J.; Zhang H.T.; Li N.; Liu T.; Zhang Y.L.; Li X.X.; Ma Q.; Qiu X.C.; Fan Q.Y.; Ma B.A.; Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett 2017,13(2),681-685
Clin Pharmacol Drug Dev Wang Z. 1 2020 10.1002/cpdd.877 Wang Z.; Liu R.; Chen L.; Wang H.; Zhou M.; Wang Y.; Qin Y.; Pharmacokinetics of Ginsenoside Rh2, the Major Anticancer Ingredient of Ginsenoside H Dripping Pills, in Healthy Subjects. Clin Pharmacol Drug Dev 2020(0),1-6
Food Chem Toxicol Gu Y 47 2257 2009 10.1016/j.fct.2009.06.013 Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol 2009,47(9),2257-2268
Drug Metab Dispos Yang Z. 39 1866 2011 10.1124/dmd.111.040006 Yang Z.; Gao S.; Wang J.; Yin T.; Teng Y.; Wu B.; You M.; Jiang Z.; Hu M.; Enhancement of oral bioavailability of 20(S)- ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 2011,39(10),1866-1872
Anal Bioanal Chem Gu Y. 386 2043 2006 10.1007/s00216-006-0857-8 Gu Y.; Wang G.J.; Sun J.G.; Jia Y.W.; Xie H.T.; Wang W.; Quantitative determination of ginsenoside Rh2 in rat biosamples by liquid chromatography electrospray ionization mass spectrometry. Anal Bioanal Chem 2006,386(7-8),2043-2053
Bioorg Med Chem Lett Wei G.Q. 22 1082 2012 10.1016/j.bmcl.2011.11.104 Wei G.Q.; Zheng Y.N.; Li W.; Liu W.C.; Lin T.; Zhang W.Y.; Chen H.F.; Zeng J.Z.; Zhang X.K.; Chen Q.C.; Structural modification of ginsenoside Rh(2) by fatty acid esterification and its detoxification property in antitumor. Bioorg Med Chem Lett 2012,22(2),1082-1085
Int J Nanomedicine Singh P. 12 4073 2017 10.2147/IJN.S125154 Singh P.; Kim Y.J.; Singh H.; Ahn S.; Castro-Aceituno V.; Yang D.C.; In situ preparation of water-soluble ginsenoside Rh2-entrapped bovine serum albumin nanoparticles: in vitro cytocompatibility studies. Int J Nanomedicine 2017,12,4073-4084
J Agric Food Chem Xu Y. 68 8545 2020 10.1021/acs.jafc.0c03698 Xu Y.; Li X.; Gong W.; Huang H.B.; Zhu B.W.; Hu J.N.; Construction of Ginsenoside Nanoparticles with pH/Reduction Dual Response for Enhancement of Their Cytotoxicity Toward HepG2 Cells. J Agric Food Chem 2020,68(32),8545-8556
Tumour Biol Li S. 35 5593 2014 10.1007/s13277-014-1739-x Li S.; Gao Y.; Ma W.; Guo W.; Zhou G.; Cheng T.; Liu Y.; EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol 2014,35(6),5593-5598
Can J Physiol Pharmacol Yuan D. 94 676 2016 10.1139/cjpp-2015-0528 Yuan D.; Yuan Q.; Cui Q.; Liu C.; Zhou Z.; Zhao H.; Dun Y.; Wang T.; Zhang C.; Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice. Can J Physiol Pharmacol 2016,94(6),676-681
Int Immunopharmacol Wang Y. 23 77 2014 10.1016/j.intimp.2014.07.028 Wang Y.; Liu Y.; Zhang X.Y.; Xu L.H.; Ouyang D.Y.; Liu K.P.; Pan H.; He J.; He X.H.; Ginsenoside Rg1 regulates innate immune responses in macrophages through differentially modulating the NF-κB and PI3K/Akt/mTOR pathways. Int Immunopharmacol 2014,23(1),77-84
Biomed Pharmacother Jiang Z. 96 378 2017 10.1016/j.biopha.2017.09.129 Jiang Z.; Yang Y.; Yang Y.; Zhang Y.; Yue Z.; Pan Z.; Ren X.; Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomed Pharmacother 2017,96,378-383
Anticancer Agents Med Chem Chen Y. 20 495 2020 10.2174/1871520619666191209091230 Chen Y.; Zhang Y.; Song W.; Zhang Y.; Dong X.; Tan M.; Ginsenoside Rh2 improves the cisplatin anti-tumor effect in lung adenocarcinoma A549 cells via superoxide and PD-L1. Anticancer Agents Med Chem 2020,20(4),495-503
Inflammopharmacology Nguyen N.H. 27 871 2019 10.1007/s10787-019-00630-4 Nguyen N.H.; Nguyen C.T.N.; Pharmacological effects of ginseng on infectious diseases. Inflammopharmacology 2019,27(5),871-883
Br J Clin Pharmacol Abdou Y. 86 1690 2020 10.1111/bcp.14316 Abdou Y.; Pandey M.; Sarma M.; Shah S.; Baron J.; Ernstoff M.S.; Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol 2020,86(9),1690-1702
J Clin Med Onoi K. 9 E1362 2020 10.3390/jcm9051362 Onoi K.; Chihara Y.; Uchino J.; Shimamoto T.; Morimoto Y.; Iwasaku M.; Kaneko Y.; Yamada T.; Takayama K.; Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. J Clin Med 2020,9(5),E1362
Clin Exp Med Xie J. 20 167 2020 10.1007/s10238-020-00609-4 Xie J.; Lin Y.; Patient-derived xenograft models for personalized medicine in colorectal cancer. Clin Exp Med 2020,20(2),167-172
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.